Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

June 16, 2014:  Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device. MST-188 has been shown …

Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute

June 16, 2014: Trovagene, Inc. (NASDAQ:   TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally …

Groundbreaking Collaborative Clinical Trial Launched

 June 16, 2014: A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the …

iHealth Launches World’s Most Portable Mobile Blood Glucose Monitor

June 12, 2014: Today, iHealth Lab Inc. announced the launch of the iHealth Align, the world’s smallest, FDA-approved mobile blood glucose monitor. The meter plugs directly into a smart phone and displays and stores readings using the iHealth Gluco-Smart app.  By displaying readings directly on the phone screen, iHealth was able to shrink the device size to just slightly larger than the circumference of a quarter. The …

Oncobiologics launches Phase I Clinical Trial for ONS-3010 Biosimilar version of Humira®

June 12, 2014: Oncobiologics, Inc. announced today that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira®. After reviewing Oncobiologics’ Clinical Trial Application, the Centrale Commissie Mensgebonden Onderzoek (CCMO), the Dutch Competent Authority, has provided a Letter of No Objection, and the Independent …

New long-term data on Cimzia® (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis

June 12 2014: New long-term data on Cimzia® (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis. New 96-week interim data cut from the RAPIDTM-PsA and -axSpA studies showed that improvements in disease activity at 24 weeks in Cimzia®-treated psoriatic arthritis and axial spondyloarthritis patients were sustained over this two year period. Post-hoc analyses suggested that …

Hunterdon Regional Cancer Center: The Only Cancer Center in New Jersey to Offer Immuno-Therapy Clinical Trial for Lung Cancer

June 11 2014: According to the American Cancer Society, lung cancer is the second most common cancer among men and women and the leading cause of death in the United States. In 2014, it is estimated that 224,210 people will be diagnosed with lung cancer. Hunterdon Regional Cancer Center was selected as the only cancer facility in New Jersey to offer a clinical …

First-of-Its-Kind Pediatric Research and Funding Collaboration to Speed Development of Medications for Autoimmune Diseases

June 11 2014: Seattle Children’s Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children’s Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis. “Funding for pediatric research lags disproportionately behind research funding for adult diseases. …

Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine

June 11 2014: Amgen (NASDAQ: AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published inThe New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR) Annual Congress in Paris on June 14, 2014 (10:15 a.m. CEST, Abstract No. SAT0404). Brodalumab is the …